• GLP-1 drugs such as Ozempic, Wegovy, and Saxenda are currently being reviewed by the FDA over concerns of a possible link to hair loss, suicidal thoughts, and aspiration.
• Regulatory action could include updating these drugs’ labels or removing them from the market, though experts agree that’s unlikely.
• The review shouldn't be a huge cause for concern, but anyone taking Ozempic or related drugs should be on the lookout for these or other side effects.

The Food and Drug Administration (FDA) is currently reviewing popular drugs such as Ozempic and Wegovy over possible links to suicidal ideation, hair loss, and aspiration.

Glucagon-like peptide-1 (GLP-1) receptor agonist drugs have been linked to side effect case reports on the FDA’s Adverse Event Reporting System (FAERS). Now, the drugs are included in an FDA review list, updated last on January 2.

The GLP-1 drugs listed include newer medications such as Wegovy and Mounjaro, as well as older type 2 diabetes drugs such as Byetta, which was first approved in 2005.

Currently, the FDA is simply “evaluating the need for regulatory action”—drug companies are not yet being asked to do anything, such as updating warnings on their package labels.

This review comes about six months after the European Medicines Agency (EMA) announced that they’d be reviewing a possible link between GLP-1 drugs and suicidal ideation after receiving about 150 case reports of the issue.

The investigation was initially supposed to wrap in November, but the EMA’s committee recently sent “further lists of questions to be addressed” to companies marketing GLP-1 drugs. The committee is set to discuss the issue again in April.

Also commenting on the potential link between semaglutide—or Ozempic and Wegovy—and suicidal ideation, a study was published on January 5 that found that the drugs did not carry a higher risk of suicidal thoughts as compared to other type 2 diabetes and weight loss drugs.

As researchers and health officials continue to dig into GLP-1 drugs and any side effects not currently listed on their labels, experts agree that the review is not a cause for concern.

“I think [the review is] appropriate, that’s what their regulatory goal is: to make sure things are safe for us,” Holly Lofton, MD, director of the medical weight management program at NYU Langone Health, told Health. “If they find that there’s anything that’s too risky, then they’ll make the recommendations.” 

What’s the Link Between GLP-1 Drugs and Alopecia, Aspiration, and Suicidal Ideation? 

Though alopecia (also know as hair loss), aspiration, and suicidal ideation were identified in the FDA’s adverse reporting system, it doesn’t necessarily confirm that these side effects were caused by the medications.

However, this FAERS reviewing system allows the FDA to stay on top of any new safety issues that come up, especially after a drug has been widely used by the public.

“These side effects weren’t shown in a clinical trial, but the clinical trial only counts for, maybe 3,000 patients on both ends. Whereas now, in the live market, we’re talking about millions of patients,” said Ebne Rafi, PharmD, clinical pharmacy specialist at the Diabetes and Obesity Center at University Hospitals in Cleveland.

This review is simply the FDA “doing their due diligence,” he told Health.

Though there’s no confirmed causation between GLP-1 drugs and the three side effects named by the FDA, previous research has made connections between them. 

With suicidal ideation and weight loss drugs, in particular, there’s a history of concerns. Some weight loss drugs have even been previously removed from the market due to heightened risk of suicidal ideation, though it’s not totally clear why they may have this effect, Lofton said.

In general, the mechanism likely has something to do with the way that weight loss medications affect the central nervous system, which can, in turn, affect mood and suicidal ideation risk, Rafi explained.

It’s worth noting that Wegovy has suicidal ideation and behavior already listed as a warning on its prescribing information, he added.

There’s also an established connection between weight loss and hair loss.

“Alopecia specifically, as I understand it, is one of the more newer side effects people are investigating,” Rafi said. “Rapid weight loss can cause certain hormonal imbalances, as well as changes in a certain type of collagen.”

These changes could end up causing hair loss in some people, though again, more research is needed. However, this phenomenon has been observed in people who undergo a large amount of weight loss via sleeve gastrectomy.

Pulmonary aspiration—where food material, saliva, or some other substance accidentally enters a person’s airway and may end up in the lungs—has a less-defined relationship with GLP-1 drugs.

The Canadian Journal of Anesthesia released a statement in July 2023 raising the alarm about patients under anesthesia accidentally inhaling gastric contents during surgery since their stomachs can’t empty fully. There doesn’t appear to be much research on any potential connection between taking GLP-1 drugs and a person’s food going down the wrong pipe.

“For example, chemical antidepressant medications have [suicidal ideation risk] as a major warning. A majority of anti-seizure medications also,” he said. “And these medications have been on the market for years and years.”

If anything, the FDA may ask companies to update their labels to include these possible side effects, experts said. This just happened in October—the FDA added a gastrointestinal side effect, ileus, to Ozempic’s label.

As for why these reviews are cropping up now, Lofton said it’s largely because of the “sheer mass of people who are taking some form of these drugs.” In other words, the number of adverse events is growing as the number of people taking the drug also increases. 

Though the FDA review is important, there’s no need for people to be “stressing out over it,” especially when, for now, there’s no proven link between GLP-1 drugs and alopecia, aspiration, or suicidal ideation, said Rafi. 

This is especially true for people who have already taken the medication and are seeing good results. 

“I have many patients who come in and they’ve been on these drugs for years with me, and they say, ‘I’m so worried about ileus.’ And I say, ‘Well, did you get ileus?’ ‘No, I didn’t get it.’ ‘Okay, well, then don’t worry,’” Lofton said.

However, patients or anyone considering taking Ozempic, Mounjaro, or a related drug should be aware of any potential risks and should be on the lookout for these or other side effects. This is especially true since every person’s experience on the medication is different, she added.

“As providers, we need to make sure to make patients aware of potential side effects, especially the serious ones,” said Lofton, “and then follow up with patients and make sure nothing untoward is putting them in a state where they have more risk than benefit.”